SCFAs can increase the expression of intestinal SLC26A6 and reduce the expression of intestinal SLC26A3, thereby affecting the absorption and excretion of oxalate and reducing the formation of urinary oxalate and calcium oxalate kidney stones (66). This evidence concerns the gene SLC26A6 and Calcium oxalate nephrolithiasis.